[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
October 23, 1995

Skin Depigmentation Related to Transdermal Clonidine Therapy

Author Affiliations

Columbus, Ohio

Arch Intern Med. 1995;155(19):2129. doi:10.1001/archinte.1995.00430190125021

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


A 66-year-old African-American woman with essential hypertension began using the clonidine hydrochloride transdermal patch (Catapres-TTS2 [transdermal therapeutic system: clonidine hydrochloride, 0.2 mg/d for 1 week]) in May 1989. Previously, she had used other antihypertensive medications, including various combinations of calcium channel blockers, β-blockers, diuretics, and angiotensin-converting enzyme inhibitors, with poor control of blood pressure. Presently, her blood pressure is better controlled, in the range of 140/90 mm Hg, with a clonidine transdermal patch (Catapres-TTS2), chlorthalidone (100 mg/d), betaxolol hydrochloride (Kerlone, 10 mg/d), and potassium chloride (Micro-K, 10 mmol/L twice a day).

Asymptomatic skin depigmentation was first noted about 1 year after therapy was initiated. The Figure shows the area of depigmentation in the left upper chest area. A similar area of depigmentation is in the right upper chest area. These sites have not been used for application of the transdermal patch for about 4 years. Despite that, repigmentation of the

First Page Preview View Large
First page PDF preview
First page PDF preview